Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1514 | 2015 |
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN H Döhner, AH Wei, FR Appelbaum, C Craddock, CD DiNardo, H Dombret, ... Blood, The Journal of the American Society of Hematology 140 (12), 1345-1377, 2022 | 1133 | 2022 |
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study AE Perl, JK Altman, J Cortes, C Smith, M Litzow, MR Baer, D Claxton, ... The Lancet Oncology 18 (8), 1061-1075, 2017 | 513 | 2017 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2 … C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, ... The lancet oncology 16 (16), 1691-1699, 2015 | 449 | 2015 |
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, ... Leukemia 26 (3), 381-389, 2012 | 443 | 2012 |
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation … A Burchert, G Bug, LV Fritz, J Finke, M Stelljes, C Röllig, E Wollmer, ... Journal of Clinical Oncology 38 (26), 2993-3002, 2020 | 407 | 2020 |
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non–high-risk acute promyelocytic leukemia: final results of the … U Platzbecker, G Avvisati, L Cicconi, C Thiede, F Paoloni, M Vignetti, ... Journal of Clinical Oncology 35 (6), 605-612, 2017 | 395 | 2017 |
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 355 | 2019 |
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes U Krug, C Röllig, A Koschmieder, A Heinecke, MC Sauerland, M Schaich, ... The Lancet 376 (9757), 2000-2008, 2010 | 348 | 2010 |
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia A Ehninger, M Kramer, C Röllig, C Thiede, M Bornhäuser, M Von Bonin, ... Blood cancer journal 4 (6), e218-e218, 2014 | 341 | 2014 |
Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting … C Röllig, M Bornhäuser, C Thiede, F Taube, M Kramer, B Mohr, W Aulitzky, ... Journal of clinical oncology 29 (20), 2758-2765, 2011 | 316 | 2011 |
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 … U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ... The Lancet Oncology 19 (12), 1668-1679, 2018 | 287 | 2018 |
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 244 | 2019 |
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial C Röllig, C Thiede, M Gramatzki, W Aulitzky, H Bodenstein, M Bornhäuser, ... Blood, The Journal of the American Society of Hematology 116 (6), 971-978, 2010 | 229 | 2010 |
How I treat hyperleukocytosis in acute myeloid leukemia C Röllig, G Ehninger Blood, The Journal of the American Society of Hematology 125 (21), 3246-3252, 2015 | 226 | 2015 |
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML N Shayegi, M Kramer, M Bornhäuser, M Schaich, J Schetelig, ... Blood, The Journal of the American Society of Hematology 122 (1), 83-92, 2013 | 213 | 2013 |
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma MA Dimopoulos, A Palumbo, P Corradini, M Cavo, M Delforge, ... Blood, The Journal of the American Society of Hematology 128 (4), 497-503, 2016 | 174 | 2016 |
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients M Bornhäuser, C Thiede, U Platzbecker, A Jenke, A Helwig, R Plettig, ... Clinical cancer research 7 (8), 2254-2262, 2001 | 134 | 2001 |
Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective … M Schaich, C Röllig, S Soucek, M Kramer, C Thiede, B Mohr, ... Journal of clinical oncology 29 (19), 2696-2702, 2011 | 133 | 2011 |
18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia F Stölzel, C Röllig, J Radke, B Mohr, U Platzbecker, M Bornhäuser, ... Haematologica 96 (10), 1552, 2011 | 127 | 2011 |